Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506839 | 0.77 | SCN9A (0.48) | GRM5HSD11B1SCN5ASCN9AHSD11B2 | |
| SCHEMBL26933937 | 0.77 | SCN9A (0.48) | GRM5HSD11B1SCN5ASCN9AHSD11B2 | |
| SCHEMBL974575 | 0.77 | HDAC1 (0.43) | HSD11B1SCN5ASCN9AHSD11B2HDAC1 | |
| SCHEMBL973976 | 0.77 | HSD11B1 (0.43) | NAMPTHSD11B1SCN5ASCN9AHSD11B2 | |
| SCHEMBL975330 | 0.72 | HSD11B1 (0.48) | HSD11B1SCN5ASCN9AHSD11B2HDAC1 | |
| SCHEMBL31631235 | 0.72 | GPR119 (0.50) | GRM5SCN5ASCN9AHDAC1HDAC6 | |
| SCHEMBL26933920 | 0.72 | GPR119 (0.50) | GRM5SCN5ASCN9AHDAC1HDAC6 | |
| SCHEMBL975484 | 0.71 | USP30 (0.49) | HSD11B1SCN5ASCN9AHSD11B2HDAC1 | |
| SCHEMBL973444 | 0.70 | HSD11B1 (0.49) | HSD11B1HSD11B2 | |
| SCHEMBL25318823 | 0.70 | NAMPT (0.52) | NAMPTGRM5GRM1BTKPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | BHMT, UGDH, NNMT | NAMPT 88/4885GRM5 1541/4885GRM1 1426/4885 |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | NAMPT 121/4885GRM5 1229/4885GRM1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.